Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
19 02 2022
19 02 2022
Historique:
received:
09
07
2021
revised:
18
08
2021
accepted:
24
08
2021
pubmed:
2
2
2022
medline:
22
3
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally. The HoFH International Clinical Collaborators registry collected data on patients with a clinical, or genetic, or both, diagnosis of HoFH using a retrospective cohort study design. This trial is registered with ClinicalTrials.gov, NCT04815005. Overall, 751 patients from 38 countries were included, with 565 (75%) reporting biallelic pathogenic variants. The median age of diagnosis was 12·0 years (IQR 5·5-27·0) years. Of the 751 patients, 389 (52%) were female and 362 (48%) were male. Race was reported for 527 patients; 338 (64%) patients were White, 121 (23%) were Asian, and 68 (13%) were Black or mixed race. The major manifestations of ASCVD or aortic stenosis were already present in 65 (9%) of patients at diagnosis of HoFH. Globally, pretreatment LDL cholesterol levels were 14·7 mmol/L (IQR 11·6-18·4). Among patients with detailed therapeutic information, 491 (92%) of 534 received statins, 342 (64%) of 534 received ezetimibe, and 243 (39%) of 621 received lipoprotein apheresis. On-treatment LDL cholesterol levels were lower in high-income countries (3·93 mmol/L, IQR 2·6-5·8) versus non-high-income countries (9·3 mmol/L, 6·7-12·7), with greater use of three or more lipid-lowering therapies (LLT; high-income 66% vs non-high-income 24%) and consequently more patients attaining guideline-recommended LDL cholesterol goals (high-income 21% vs non-high-income 3%). A first major adverse cardiovascular event occurred a decade earlier in non-high-income countries, at a median age of 24·5 years (IQR 17·0-34·5) versus 37·0 years (29·0-49·0) in high-income countries (adjusted hazard ratio 1·64, 95% CI 1·13-2·38). Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature ASCVD risk. Greater use of multi-LLT regimens is associated with lower LDL cholesterol levels and better outcomes. Significant global disparities exist in treatment regimens, control of LDL cholesterol levels, and cardiovascular event-free survival, which demands a critical re-evaluation of global health policy to reduce inequalities and improve outcomes for all patients with HoFH. Amsterdam University Medical Centers, Location Academic Medical Center; Perelman School of Medicine at the University of Pennsylvania; and European Atherosclerosis Society.
Sections du résumé
BACKGROUND
Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally.
METHODS
The HoFH International Clinical Collaborators registry collected data on patients with a clinical, or genetic, or both, diagnosis of HoFH using a retrospective cohort study design. This trial is registered with ClinicalTrials.gov, NCT04815005.
FINDINGS
Overall, 751 patients from 38 countries were included, with 565 (75%) reporting biallelic pathogenic variants. The median age of diagnosis was 12·0 years (IQR 5·5-27·0) years. Of the 751 patients, 389 (52%) were female and 362 (48%) were male. Race was reported for 527 patients; 338 (64%) patients were White, 121 (23%) were Asian, and 68 (13%) were Black or mixed race. The major manifestations of ASCVD or aortic stenosis were already present in 65 (9%) of patients at diagnosis of HoFH. Globally, pretreatment LDL cholesterol levels were 14·7 mmol/L (IQR 11·6-18·4). Among patients with detailed therapeutic information, 491 (92%) of 534 received statins, 342 (64%) of 534 received ezetimibe, and 243 (39%) of 621 received lipoprotein apheresis. On-treatment LDL cholesterol levels were lower in high-income countries (3·93 mmol/L, IQR 2·6-5·8) versus non-high-income countries (9·3 mmol/L, 6·7-12·7), with greater use of three or more lipid-lowering therapies (LLT; high-income 66% vs non-high-income 24%) and consequently more patients attaining guideline-recommended LDL cholesterol goals (high-income 21% vs non-high-income 3%). A first major adverse cardiovascular event occurred a decade earlier in non-high-income countries, at a median age of 24·5 years (IQR 17·0-34·5) versus 37·0 years (29·0-49·0) in high-income countries (adjusted hazard ratio 1·64, 95% CI 1·13-2·38).
INTERPRETATION
Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature ASCVD risk. Greater use of multi-LLT regimens is associated with lower LDL cholesterol levels and better outcomes. Significant global disparities exist in treatment regimens, control of LDL cholesterol levels, and cardiovascular event-free survival, which demands a critical re-evaluation of global health policy to reduce inequalities and improve outcomes for all patients with HoFH.
FUNDING
Amsterdam University Medical Centers, Location Academic Medical Center; Perelman School of Medicine at the University of Pennsylvania; and European Atherosclerosis Society.
Identifiants
pubmed: 35101175
pii: S0140-6736(21)02001-8
doi: 10.1016/S0140-6736(21)02001-8
pmc: PMC10544712
mid: NIHMS1928953
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04815005']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
719-728Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL059407
Pays : United States
Investigateurs
Tycho R Tromp
(TR)
Merel L Hartgers
(ML)
G Kees Hovingh
(GK)
Antonio J Vallejo-Vaz
(AJ)
Kausik K Ray
(KK)
Handrean Soran
(H)
Tomas Freiberger
(T)
Stefano A Bertolini
(SA)
Mariko Harada-Shiba
(M)
Jing Pang
(J)
Gerald F Watts
(GF)
Susanne Greber-Platzer
(S)
Martin Mäser
(M)
Thomas M Stulnig
(TM)
Christoph F Ebenbichler
(CF)
Khalid Bin Thani
(K)
David Cassiman
(D)
Olivier S Descamps
(OS)
Daisy Rymen
(D)
Peter Witters
(P)
Raul D Santos
(RD)
Liam R Brunham
(LR)
Gordon A Francis
(GA)
Jacques Genest
(J)
Robert A Hegele
(RA)
Brooke A Kennedy
(BA)
Isabelle Ruel
(I)
Mark H Sherman
(MH)
Long Jiang
(L)
Luya Wang
(L)
Željko Reiner
(Ž)
Vladimir Blaha
(V)
Richard Ceska
(R)
Jana Dvorakova
(J)
Lubomir Dlouhy
(L)
Pavel Horak
(P)
Vladimir Soska
(V)
Lukas Tichy
(L)
Robin Urbanek
(R)
Helena Vaverkova
(H)
Michal Vrablik
(M)
Stanislav Zemek
(S)
Lukas Zlatohlavek
(L)
Sameh Emil
(S)
Tarek Naguib
(T)
Ashraf Reda
(A)
Sophie Béliard
(S)
Eric Bruckert
(E)
Antonio Gallo
(A)
Moses S Elisaf
(MS)
Genovefa Kolovou
(G)
Hofit Cohen
(H)
Ronen Durst
(R)
Eldad J Dann
(EJ)
Avishay Elis
(A)
Osama Hussein
(O)
Eran Leitersdorf
(E)
Daniel Schurr
(D)
Nitika Setia
(N)
Ishwar C Verma
(IC)
Mohammed D Alareedh
(MD)
Mutaz Al-Khnifsawi
(M)
Ali F Abdalsahib Al-Zamili
(AF)
Sabah H Rhadi
(SH)
Foaad K Shaghee
(FK)
Marcello Arca
(M)
Maurizio Averna
(M)
Andrea Bartuli
(A)
Marco Bucci
(M)
Paola S Buonuomo
(PS)
Paolo Calabrò
(P)
Sebastiano Calandra
(S)
Manuela Casula
(M)
Alberico L Catapano
(AL)
Angelo B Cefalù
(AB)
Arrigo F G Cicero
(AFG)
Sergio D'Addato
(S)
Laura D'Erasmo
(L)
Alessia Di Costanzo
(A)
Tommaso Fasano
(T)
Marta Gazzotti
(M)
Antonina Giammanco
(A)
Gabriella Iannuzzo
(G)
Anastasia Ibba
(A)
Emanuele A Negri
(EA)
Andrea Pasta
(A)
Chiara Pavanello
(C)
Livia Pisciotta
(L)
Claudio Rabacchi
(C)
Carlo Ripoli
(C)
Tiziana Sampietro
(T)
Francesco Sbrana
(F)
Fulvio Sileo
(F)
Patrizia Suppressa
(P)
Patrizia Tarugi
(P)
Chiara Trenti
(C)
Maria G Zenti
(MG)
Mika Hori
(M)
Mahmoud H Ayesh
(MH)
Sami T Azar
(ST)
Fadi F Bitar
(FF)
Akl C Fahed
(AC)
Elie M Moubarak
(EM)
Georges Nemer
(G)
Hapizah M Nawawi
(HM)
Ramón Madriz
(R)
Roopa Mehta
(R)
Arjen J Cupido
(AJ)
Joep C Defesche
(JC)
M Doortje Reijman
(MD)
Jeanine E Roeters-van Lennep
(JE)
Erik S G Stroes
(ESG)
Albert Wiegman
(A)
Linda Zuurbier
(L)
Khalid Al-Waili
(K)
Fouzia Sadiq
(F)
Krzysztof Chlebus
(K)
Mafalda Bourbon
(M)
Isabel M Gaspar
(IM)
Katarina S Lalic
(KS)
Marat V Ezhov
(MV)
Andrey V Susekov
(AV)
Urh Groselj
(U)
Min-Ji Charng
(MJ)
Weerapan Khovidhunkit
(W)
Melih Aktan
(M)
Bulent B Altunkeser
(BB)
Sinan Demircioglu
(S)
Melis Kose
(M)
Cumali Gokce
(C)
Osman Ilhan
(O)
Meral Kayikcioglu
(M)
Leyla G Kaynar
(LG)
Irfan Kuku
(I)
Erdal Kurtoglu
(E)
Harika Okutan
(H)
Osman I Ozcebe
(OI)
Zafer Pekkolay
(Z)
Saim Sag
(S)
Osman Z Salcioglu
(OZ)
Ahmet Temizhan
(A)
Mustafa Yenercag
(M)
Mehmet Yilmaz
(M)
Hamiyet Yilmaz Yasar
(H)
Olena Mitchenko
(O)
Alexander R M Lyons
(ARM)
Christophe A T Stevens
(CAT)
Julie A Brothers
(JA)
Lisa C Hudgins
(LC)
Christina Nguyen
(C)
Rano Alieva
(R)
Aleksandr Shek
(A)
Doan-Loi Do
(DL)
Ngoc-Thanh Kim
(NT)
Hong-An Le
(HA)
Thanh-Tung Le
(TT)
Mai-Ngoc T Nguyen
(MT)
Thanh-Huong Truong
(TH)
Dirk J Blom
(DJ)
Frederick J Raal
(FJ)
Marina Cuchel
(M)
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests SB declares no competing interests. DJB reports research grants from Amgen, Amryt, AstraZeneca, Sanofi, and Regeneron; lecture fees and personal fees from Amgen, Sanofi-Aventis and Novartis; participation in advisory board for Amryt (Chair of the LOWER study steering committee); and being member of the executive committee of the Lipid and Atherosclerosis Society of South Africa. MC reports institutional support for the conduction of clinical trials from Regeneron Pharmaceuticals, Akcea, and Regenxbio; consulting fees from Amryt Pharma; and support from NIH/NHLBI grant (P01HL059407). TF reports personal fees from Novartis, Sanofi, and Amgen; and that he was partly supported by the Ministry of Health, Czech Republic, grant number NU20-02-00261. MH-S reports research grants from Recordati and Kaneka; personal fees from Amgen, Astellas, Recordati, Merck Sharp & Dohme, and Sanofi; being on the advisory board for New Amsterdam Pharma and Medicine Company and Scilence Therapeutics; being chairperson Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Japanese Ministry of Health, Labor, and Welfare; being chairperson of the Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia; and owning stock options of Liid Pharma. MLH reports lecture fees from Sanofi, outside the submitted work. GKH reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, EU, and the Klinkerpad fonds; institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company; speaker's bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron until April 2019 (fees paid to the academic institution); and part-time employment at Novo Nordisk, Denmark since April, 2019. FJR reports consulting fees, lecturing fees, and advisory board fees from Amgen, Sanofi-Aventis, Regeneron, Novartis and Lib Therapeutics outside the submitted work; and being member of the International Atherosclerosis Society. KKR reports institutional research grants from Amgen, Sanofi, Daiichi Sankyo, Regeneron, and Pfizer; consulting fees and lecturing fees from Amgen, Sanofi, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Kowa, Silence Therapeutics, New Amsterdam, Esperion, Daiichi Sankyo, Bayer, Abbott, Resverlogix, Medicines Company, Eli Lilly, Algorithm, Merck, Sharp & Dohme, AbbVie, and Viatris, outside the submitted work. HS reports research grants from Amgen, Merck, Sharp & Dohme, Synageva, Amryt, Alexion, and Akcea; consulting fees from Amgen, Alexion, Daiichi Sankyo, Pfizer, and Akcea; and speaker fees from Amgen, Daiichi Sankyo, Sanofi, and Akcea. TRT declares no competing interests. AJV-V reports participation in research grants to Imperial College London or European Atherosclerosis Society, or both, from Pfizer, Amgen, Merck Sharp & Dohme, Sanofi-Aventis, Daiichi Sankyo, and Regeneron; personal fees for consulting from Bayer and Regeneron; and honoraria for lectures from Amgen, Mylan, and Akcea; outside the submitted work.
Références
Circulation. 2020 Jun 2;141(22):1742-1759
pubmed: 32468833
JAMA. 2009 Nov 11;302(18):1993-2000
pubmed: 19903920
J Clin Med. 2020 Jan 14;9(1):
pubmed: 31947532
J Clin Lipidol. 2017 Jul - Aug;11(4):858-871.e3
pubmed: 28572002
Eur Heart J. 2014 Aug 21;35(32):2146-57
pubmed: 25053660
Eur Heart J. 2018 Apr 7;39(14):1162-1168
pubmed: 29106543
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680
pubmed: 30071997
J Clin Lipidol. 2019 Jul - Aug;13(4):608-617
pubmed: 31255589
N Engl J Med. 2020 Aug 20;383(8):711-720
pubmed: 32813947
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2508-2515
pubmed: 32757650
Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290
pubmed: 28215937
Atherosclerosis. 2016 Dec;255:128-139
pubmed: 27839699
J Clin Lipidol. 2016 Jul-Aug;10(4):953-961
pubmed: 27578128
Atherosclerosis. 2018 Oct;277:66-71
pubmed: 30176566
Atherosclerosis. 2020 Nov;312:72-78
pubmed: 32977124
J Am Coll Cardiol. 2018 Jan 23;71(3):279-288
pubmed: 29348020
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566
pubmed: 32439005
Atherosclerosis. 2017 Feb;257:86-89
pubmed: 28126585
J Am Coll Cardiol. 2020 Feb 18;75(6):565-574
pubmed: 32057369
Heart Lung Circ. 2021 Mar;30(3):324-349
pubmed: 33309206
Adv Ther. 2019 Jul;36(7):1786-1811
pubmed: 31102204
J Clin Lipidol. 2019 May - Jun;13(3):455-467
pubmed: 30928440
Eur Heart J. 2015 Mar 1;36(9):560-5
pubmed: 24585268
Atherosclerosis. 2018 Oct;277:234-255
pubmed: 30270054
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Lancet Diabetes Endocrinol. 2020 Jan;8(1):50-67
pubmed: 31582260
Lancet. 2013 Jan 5;381(9860):40-6
pubmed: 23122768
Atherosclerosis. 2020 Apr;299:24-31
pubmed: 32199148